An AI-based toolkit that Predicts key Genomic Signatures from H&E Whole Slide Images(WSI) to identify potential patients to benefit from Immunotherapy, Platinum based treatment, and PARP inhibitor therapy

Routine Histopathology images of biopsied tissue sections are converted into heatmaps which in turn provides predictive molecular-genomic biomarker results, that help physicians to take quick treatment decisions

OncoPredikt is a one-step solution for an OncoPathologist to scan the tissue section slide images and derive molecular biomarker information within minutes.

Positively impacting digital pathology through the power of AI/ML

Impact on turn around time Molecular genetic predictive markers from glass slides within 10 minutes

Impact on cost
It costs just one tenth that of NGS-based genetic test

Impact on accessibility
Allows pathologists to access results from their own desks

Accelerating Precision
Automating image prediction and improving efficacy

OncoPredikt is custom developed and validated against global databases and thousands of clinical samples worldwide.

  • OncoPredikt – HRD: Provides prediction of Homologus Recombinant Deficiency from ovarian biopsy images

  • OncoPredikt – Lung: Provides prediction of 11 genetic mutations pertaining to Non-Small Cell Lung Cancer, which are decisive for therapeutic decision

  • OncoPredikt – Breast: Provides risk of recurrence for early stage (Node negative) ER positive & HER2 negative breast cancers. Validated against OncoTypeDx and CanAssist

  • OncoPredict – IO: Provides prediction of immunotherapy markers (PDL1, MSI, TMB, TILs and KRAS) on the biopsy samples of solid tumors

Predicting key genomic signatures

OncoPredikt – HRD:
For all cases of Serous adenocarcinoma of the ovaries

OncoPredikt – Lung:
For all cases of Non-Small cell Lung Cancers

OncoPredikt – Breast:
For all cases of ER/PR positive Her2 Negative infiltrating / intra ductal carcinoma of breast

OncoPredict – IO:
For different solid tumors such as lung, colon, breast, ovarian cancers

Features of the OncoPredikt report:

  • Clear unambiguous results of predictive biomarkers based on thousands of validation samples/cases

  • AI based delineation of highly representative microscopic regions of the tumor

  • Digital heatmap of the tissue micrograph alongside H&E stained biopsy image

  • Chronological summary allows the reviewer / physician to get a snapshot of the clinical history of the given case

Coverage:

OncoPredikt – HRD
BRCA and non-BRCA Homologous recombinant Pathway genes, Genome wide LOH scoring as well as TAI and LST

OncoPredikt – Lung
Includes predictions for the following mutations: EGFR, KRAS, ALK, MET, ROS, STK11 and RET

OncoPredikt – Breast
Provides recurrence risk score matched against Oncotype Dx

OncoPredikt – IO
Predicts patients’ eligibility for immunotherapy using five biomarkers: PD-L1, MSI, TMB, TILs, KRAS

FAQs

  • Tissue section (H&E stained) glass slide or high resolution histomicrograph image

  • A minimum of 30% tumor content must be detectable on the slide or image

  • No. The OncoPredikt test is based on AI/ML based analysis of H&E stained sections

  • While a pathologist who has access to the iCARE platform can get OncoPredikt analysis for tissue biopsy images in real time (within 10 minutes). Incase images/slides are sent to our central lab, you will get the results within 48 working hours